What the FDA labels say about taking them together
Citalopram and fingolimod
Fingolimod's FDA label of July 22, 2026 names citalopram in its drug interactions section; the citalopram labels PlainMeds reads (2) do not name fingolimod. The fingolimod label: “Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes should be monitored overnight with …”
Check it at the source: the citalopram FDA label on DailyMed (effective October 9, 2023, Allergan, Inc.); the fingolimod FDA label on DailyMed (effective July 22, 2026, Novartis Pharmaceuticals Corporation).
What does the citalopram label say about fingolimod?
Citalopram's label (effective October 9, 2023) and its 1 other brand-application label do not name fingolimod in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Celexa), NDA020822 (Abbvie), as published by Allergan, Inc., effective October 9, 2023 (SPL set 4259d9b1-de34-43a4-85a8-41dd214e9177), via openFDA; the full label on DailyMed
What does the fingolimod label say about citalopram?
Fingolimod label, drug interactionsSince initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT-prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility [see Dosage and Administration (2.4), Warnings and Precautions (5.1)].
Fingolimod label, warnings and precautionsSince initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients with a prolonged QTc interval (> 450 msec adult and pediatric males, > 470 msec adult females, or > 460 msec pediatric females) before dosing or during 6-hour observation, or at additional risk for QT prolongation (e.g., hypokalemia, hypomagnesemia, congenital long-QT syndrome), or on concurrent therapy with QT prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility.
Source: FDA drug label (Tascenso Odt, NDA214962), Cycle Pharmaceuticals Ltd, effective January 20, 2026 (SPL set bf8e7f89-ea09-43c7-a7eb-e44724350721), via openFDA
Source: FDA drug label (Gilenya), Novartis Pharmaceuticals Corporation, effective July 22, 2026 (SPL set cc9e1c8c-0e2b-44e2-878b-27057f786be9), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Citalopram | Fingolimod | |
|---|---|---|
| Labeled for | Depression | Multiple sclerosis |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.026 per tablet 10 mg tablet | $1.58 per capsule 0.5 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once